MGI Tech Co., Ltd. (MGI), a global leader in life science innovation, has announced a strategic partnership with Negedia, an initiative launched by Fondazione Telethon, to enhance access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics in Italy. This collaboration marks a significant step forward in accelerating precision medicine and biomedical research, particularly in the areas of rare diseases and oncology.
Negedia is focused on integrating genomic and molecular insights into healthcare to improve prevention, diagnosis, and treatment. It serves researchers, clinicians, and laboratories with advanced technologies that enable immediate, data-driven decision-making. Through this partnership, MGI will supply its high-throughput DNBSEQ-T7 sequencing platform, allowing Negedia to significantly expand its analytical and research capabilities.
The DNBSEQ-T7 platform supports high-resolution spatial transcriptomic analysis, enabling researchers to capture the entire transcriptome—RNA molecules transcribed from the genome—while preserving the structural integrity of tissues. This level of detail allows scientists to study gene expression in precise spatial contexts, offering new perspectives on disease mechanisms and cellular interactions.
A key component of this initiative is STOmics' proprietary Stereo-seq (SpaTial Enhanced REsolution Omics – sequencing) technology, which provides nanometer-scale resolution and a centimeter-scale field-of-view (up to 13cm x 13cm), surpassing the limits of conventional single-cell analysis. The technology uses innovative silicon chips embedded with millions of geographically localized points to trace the exact origin of mRNA molecules, providing unprecedented insights into tissue architecture and gene activity.
Negedia has become an officially certified service provider for Stereo-seq, ensuring high standards in data accuracy and reliability. Its team has undergone specialized training in cryosectioning and sample preparation, and established dedicated labs optimized for STOmics protocols. This ensures robust, reproducible results across applications such as oncology, neuroscience, developmental biology, and personalized medicine.
Prof. Davide Cacchiarelli, Chief Scientific Officer at Negedia, highlighted the value of this unbiased and exploratory method, stating that the integration of Stereo-seq into their research toolbox will unlock new possibilities for discovery in biomedical science.
Dr. Christian Zimmerman, Vice President of Sales, Europe and Africa at MGI, emphasized that providing access to cutting-edge sequencing tools is essential for enabling deeper biological insights. He noted that spatial transcriptomics represents a breakthrough in understanding gene expression and tissue function, particularly in rare diseases and complex disorders.
This partnership not only strengthens Italy’s research capabilities but also sets the stage for more accurate diagnoses, tailored therapies, and preventive, data-driven healthcare, advancing the broader mission of precision medicine.